JNJ

Market: NYSE | Country: United States | Currency: $

Johnson & Johnson is one of the world's largest global healthcare groups, focused after the Kenvue spin-off (2023) on two high-margin segments: Innovative Medicine (oncology, immunology, neuroscience, cardiovascular) and MedTech (medical devices, robotic surgery, orthopedics, vision care). With 2025 sales of $94.19B and 2026 guidance at a midpoint of ~$100.5B, it operates in all major global markets with more than 75% of revenue from #1 or #2 positions in their respective categories. Classified in the GICS Health Care / Pharmaceuticals sector, listed on the NYSE with the United States as its primary country of operation.

RED FLAG: ABSENT

No fatal structural risk identified. The balance sheet is solid ($19.71B of cash, recurring FCF), access to funding is broad, and the legal risk linked to talc — although relevant — is a known burden, broadly provisioned in the accounts and does not represent an imminent danger to business continuity.

AI DISRUPTION RISK: LOW

Artificial intelligence acts as an accelerator in the company's divisions — improving drug discovery in oncology, optimizing trial design and enhancing the precision of MedTech robotic systems — without constituting a threat to the basic business model.

B1.1 — Leadership and systemic role: 8.90

Johnson & Johnson holds #1 or #2 positions in more than 75% of the segments in which it operates, with a dominant presence in oncology (multiple myeloma with Darzalex), immunology (Stelara, Tremfya) and MedTech (orthopedics, Velys and Ottava robotic surgery). Its role is systemic: hospitals, governments and healthcare systems consider it an almost irreplaceable partner. Multi-platform diversification between pharma and devices reduces dependence on a single asset and provides a structural stability that few competitors can replicate.

B1.2 — Customers and barriers to entry: 8.50

Barriers are formidable on both fronts. In pharma, patent protection, R&D scale ($13B+ annually) and multi-year regulatory processes make entry for new competitors extremely expensive. In MedTech, hospital switching costs are high: surgeon training on proprietary systems, the installed base and multi-year contracts with healthcare facilities create structural lock-in that is difficult to erode. In 2025 the group invested more than $32B overall between R&D and strategic M&A, further consolidating the moat.

B1.3 — Business economics: 8.50

Economic fundamentals are high quality: net margin ~28%, structurally >30% ROE, 2025 sales at $94.19B with double-digit growth in key areas. Cash generation is stable and predictable — TTM FCF $19.70B despite the year's M&A capex. The post-Kenvue portfolio is more concentrated on high-margin divisions, improving the overall quality of the economic profile. The main caution factor is the imminent Stelara patent cliff, which the market will monitor to assess the pipeline's ability to offset the revenue decline.

B1.4 — Balance sheet and resilience: 8.25

The balance sheet remains among the strongest globally — JNJ is one of the very few companies in the world with an AAA credit rating. Cash of $19.71B comfortably covers debt service. However, the profile is less of a "net cash fortress" than in the past: gross debt rose to $47.90B to finance the acquisition of Intra-Cellular Therapies (~$14.6B, 2025), bringing net debt to ~$27.8B. This is not an alarm signal, but it marginally reduces room for maneuver compared with the years before the acquisition.

B2.1 — Sector cycle: 6.50

The healthcare/pharma sector in 2026 presents 3/5 positive factors out of 5: stable/positive earnings estimate revisions (A ✓), aggregate revenue trends growing single-digit (B ✓), structurally inelastic demand (C ✓). Negative factors: high capex to support innovation (D ✗) and a progressively tightening regulatory regime — Medicare price renegotiation through IRA, tariff pressure on drugs imported into the U.S., tighter international scrutiny (E ✗). The cycle is defensive and stable, not euphoric.

B2.2 — Structural trends: 7.75

Secular drivers are solid and well defined: global demographic aging, rising incidence of chronic diseases, expansion of precision medicine, surgical robotics and AI-accelerated drug discovery. These are decade-long trends that structurally support demand for both JNJ segments. The distinction between the defensive short-term cycle and the long-term secular trend is clear and positive.

B2.3 — Competitive positioning in the cycle: 7.60

JNJ shows low relative volatility (beta 0.33), YoY performance above the sector (+46% at 1 year) and 2026 guidance growing versus 2025. Its targeted-acquisition strategy (Intra-Cellular for neuroscience, MedTech expansion) allows it to gain ground versus peers in higher-margin segments. The exit from the low-growth consumer division has made the business profile more responsive and less burdened.

B2.4 — Exogenous risks: 5.50

Exogenous risks are present and pressing. Medicare drug-price renegotiation imposed by the IRA structurally compresses pricing power in the U.S. market. Potential tariffs on imported drugs add uncertainty to the global supply chain. Historical talc litigation, although not fatal, creates a reputational and legal overhang that limits multiples. Geographic and product diversification mitigates — but does not eliminate — exposure to these factors.

B3.1 — Intrinsic Fair Value: 5.29

Weighted Fair Value: $237.90 | Estimates: 4/4

Current price $240.77 vs FV $237.90 → premium +1.21% → Fair Value range (±9.99%). Base Score: 5.25.

Dispersion: 77.6% [Type: MIXED — Alpha Spread and GuruFocus indicate overvaluation; SWS undervaluation] → Penalty: -0.50.

Post-penalty score: 4.75.

Score includes Excellence Premium +0.54 (Business Score 8.54/10) → final B3.1: 5.29 (cap 6.50 not applied).

B3.2 — Analyst consensus: 6.05

Consensus_Score: 6.10 (BUY_Score 6.10 − SELL_Penalty 0.00).

Upside_Score: 6.00 (range: Upside 5–9.99%).

B3.2 = (6.10 + 6.00) / 2 = 6.05

Sell-side consensus is moderately constructive: no SELL, majority Buy, with an average target offering limited but positive upside versus the current price.

B3.3 — Relative valuation: 5.00

The TTM P/E of 21.83x compares with a 5y historical average of ~21.29x (+2.5% — marginal, slightly unfavorable) and a large-cap pharma peer average of 22.8x (-4.2% — slightly favorable). The AND condition is not satisfied: JNJ is above its recent history. Gaps are contained in both directions, placing the stock in a zone of relative valuation neutrality with no clear directional signals.

B3.4 — FCF & Net Shareholder Yield: 6.50

TTM FCF: $19.70B (Annual Report 2025) | Market Cap: $580.3B.

FCF Yield: 3.39% | Dividend Yield: 2.16% ($5.20/share annual, 63rd consecutive year of growth) | Net buyback: ~0.00%.

Net Shareholder Yield: 5.55% → 4–6% range → Base score: 6.50.

Profile: Solid business, positive outlook, full valuation.

Competitive Advantage and Moat

Wide and stable moat. JNJ's competitive advantage rests on three structural pillars: a patent portfolio of exceptional value in Innovative Medicine, high switching costs in the MedTech division (installed base, clinical training, hospital contracts), and R&D scale that enables outsourcing of early-stage risk through acquisitions of high-potential molecules. The moat appears stable today, with expansion potential through surgical robotics (Ottava) and the oncology pipeline. The main structural threat is the Stelara patent cliff, whose impact will be the real test of the pipeline's ability to offset expiring revenue.

General Cycle and Competitive Dynamics

The healthcare sector maintains its defensive characteristics in the macroeconomic cycle, but 2026 adds variables: pressure on U.S. drug prices (IRA), tariff risk on the global supply chain and greater international regulatory scrutiny. JNJ enters this phase with beta 0.33, growing revenue and a portfolio more concentrated on high-margin segments after the Kenvue divestiture. Competitive dynamics see large players consolidating their advantage through strategic acquisitions, a pattern in which JNJ demonstrated effectiveness in 2025.

Catalysts and Future Opportunities (Bull Case)

The main catalysts are: 2026 growth guided to ~$100.5B of sales, commercial expansion of Velys and Ottava robotic systems in MedTech, positive updates on the oncology pipeline (mCRPC, multiple myeloma), dividend growth for the 63rd consecutive year, and the possibility that the market begins to price JNJ as a long-term defensive compounder rather than as a mature pharma stock under patent-cliff pressure.

Risks (Bear Case)

The most relevant risk is loss of exclusivity on Stelara — the market will closely monitor the pipeline's ability to replace these revenues over the next 12–24 months. Price pressures imposed by the IRA and potential tariffs on the pharmaceutical supply chain could compress margins more sharply than expected. Talc litigation, while managed, creates a persistent overhang. Finally, debt increased after the Intra-Cellular acquisition reduces financial flexibility compared with the past.

Solid business, fair valuation. Limited opportunity at the current price. NEUTRAL.

Why it could be an opportunity

Buying JNJ today means entering one of the world's strongest healthcare assets, with an AAA balance sheet, recurring FCF of $19.70B and a dividend increased uninterruptedly for 63 years. Sell-side consensus is constructive with an average target of $253.87 (+5.4%), while the oncology pipeline and surgical robotics offer concrete medium-term catalysts. For a quality-oriented investor with a multi-year horizon, JNJ represents a defensive long-term position with visible incremental growth.

Why it could be a risk

The stock trades at fair value versus intrinsic valuation models, with high FV dispersion (77.6%) reflecting genuine uncertainty about value. The price is near annual highs ($251.71 peak), offering virtually no margin of safety. The Stelara patent cliff and regulatory pressure on U.S. drug prices are structural headwinds that could keep multiples compressed for an extended period.

Price Target Table

This analysis is produced by the Score³ system for informational purposes only and does not constitute financial advice, a solicitation to invest, or a trading or investment recommendation. Data is collected from public sources and may contain errors or delays. Fair value estimates and price targets are model-based projections subject to significant uncertainty and do not represent certain forecasts. Investing involves risks, including the possible loss of invested capital. Always verify critical data against primary sources before making any investment decision. Past performance is not indicative of future results.